UBS Group
TLX

UBS Group’s Telix Pharmaceuticals TLX Stock Holding History

UBS Group’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$309K Buy
32,300
+30,336
+1,545% +$231K ﹤0.01% 6382
2025
Q4 		$14.7K Sell
1,964
-3,601
-65% -$34.7K ﹤0.01% 7984
2025
Q3 		$53.3K Sell
5,565
-556
-9% -$6.81K ﹤0.01% 7516
2025
Q2 		$98.4K Buy
6,121
+2,470
+68% +$41.5K ﹤0.01% 7254
2025
Q1 		$61.2K Sell
3,651
-79
-2% -$1.38K ﹤0.01% 7429
2024
Q4 		$57.4K Buy
+3,730
New +$58.6K ﹤0.01% 7215

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $6.97B AUM 29.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

UBS Group's TLX Position: Q1 2026 in Review

UBS Group increased its Telix Pharmaceuticals (TLX) stake by 1,545% in Q1 2026, buying an estimated $231K and bringing the position to 32,300 shares worth $309K. The position accounts for ﹤0.01% of the portfolio, ranked #6382.

UBS Group first reported a position in TLX in Q4 2024 and has held it in 6 quarters since. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • UBS Group held 32,300 shares of Telix Pharmaceuticals worth $309K as of Q1 2026.
  • UBS Group bought 30,336 Telix Pharmaceuticals shares in Q1 2026, an estimated $231K.
  • Telix Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6382 holding.
  • UBS Group first reported a position in Telix Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.